Northwestern University Human Resources

A Nature study led by MD Anderson researchers found that ovarian cancer patients with PPP2R1A mutations had significantly better overall survival when treated with immune checkpoint blockade therapy.

The TRUST trial, the first phase III randomized study comparing surgical timing in advanced ovarian cancer, demonstrated statistically significant improvement in progression-free survival with primary cytoreductive surgery versus interval surgery (22.1 vs 19.7 months, HR=0.80, P=.018).

The FDA approved an expanded indication for Sanofi's MenQuadfi meningococcal vaccine to include children aged 6 weeks to 23 months, making it the only MenACWY vaccine with no upper age limit.

Scientists have developed the first wireless device capable of remotely activating photoactivable drugs, demonstrating effective pain management using photolabile morphine without typical opioid side effects.

Northwestern University researchers screened nearly 500 FDA-approved compounds and identified piperacillin as a potentially more effective Lyme disease treatment than current standard doxycycline therapy.

Grove Biopharma, a Northwestern University spinout developing therapies for intracellular disease targets, has secured $30 million in Series A financing to fuel its expansion and research initiatives.

Northwestern University researchers found that NU-9, an experimental drug approved for ALS clinical trials, effectively reduces toxic protein buildup in Alzheimer's disease animal models.

Sibel Health has closed a $30 million Series C financing round led by the Steele Foundation for Hope with significant participation from Dräger, positioning the company for commercial expansion.

Northwestern University researchers are conducting a Phase 3 clinical trial (SPARX3) to evaluate how different intensities of aerobic exercise affect disease progression in newly diagnosed, unmedicated Parkinson's patients.

The FDA has cleared Northwestern University's IND application for Calidi Biotherapeutics' CLD-101, a stem cell-based platform delivering oncolytic viruses for treating high-grade glioma, with Phase 1b/2 trials starting late 2024.